Former U.S. Assistant Secretary of Defense Andrew Weber Appointed to Zeteo Tech BOD

Former U.S. Assistant Secretary of Defense Andrew Weber has been appointed to Zeteo Tech board of directors. The news was announced today. Mr. Weber served as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs under President Obama.

“Andy has dedicated much of his professional career working to strengthen our Nation’s security and response to nuclear, chemical, and biological threats,” said Wayne Bryden, PhD, President and CEO of Zeteo Tech. “We are delighted that he is joining the Board, and his unmatched wealth of knowledge and experience will be greatly utilized as Zeteo continues to grow its commercial and government offerings.”

Zeteo Tech’s proprietary digitalMALDI® technology pushes mass spectrometry innovation to a new level of sensitivity and specificity, enabling its instruments to obtain biomarker measurements from individual particles in the bioaerosol and then complete a biomarker-specific molecular identification in seconds. A combination of proprietary bioaerosol processing and MALDI mass spectrometry enables the technology’s ground-breaking advances to eliminate environmental background. By discretizing the sample in time, the analysis is exceptionally fast, sensitive and specific.

In addition to Mr. Weber’s public service as the Assistant Secretary of Defense for Nuclear, Chemical & Biological Defense Programs, he was a driving force behind Nunn-Lugar Cooperative Threat Reduction efforts to remove weapons-grade uranium from Kazakhstan and Georgia and nuclear-capable MiG-29 aircraft from Moldova, to reduce biological weapons threats, and to destroy Libyan and Syrian chemical weapons stockpiles. Mr. Weber also coordinated leadership of the international Ebola response for the U.S. Department of State.

Prior to joining the Pentagon as Advisor for Threat Reduction Policy in December 1996, Mr. Weber was posted abroad as a U.S. Foreign Service Officer in Saudi ArabiaGermanyKazakhstan, and Hong Kong. Mr. Weber is an independent consultant and a Strategic Advisor for Ginkgo BioWorks. He serves on the Boards of Healthcare Ready and the Arms Control Association, and the James Martin Center for Non-proliferation Studies International Advisory Council.

Mr. Weber taught at the Georgetown University Graduate School of Foreign Service for seven years and was a Senior Fellow at the Harvard Kennedy School’s Belfer Center for Science and International Affairs. Mr. Weber graduated from Cornell University and holds a Master of Science in Foreign Service (MSFS) degree from Georgetown University. He is a member of the Council on Foreign Relations and a Senior Fellow at the Council on Strategic Risks, a non-partisan, non-profit think tank working against existential threats.

 

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.